Human bronchoalveolar macrophage cytotoxicity for cultured human lung-tumour cells. by Swinburne, S. et al.
Br. J. Cancer (1982) 46, 625
HUMAN BRONCHOALVEOLAR MACROPHAGE CYTOTOXICITY FOR
CULTURED HUMAN LUNG-TUMOUR CELLS
S. SWINBURNEt, M. MOORE* AND P. COLE
From the Host Defence Unit, Department of Medicine, Cardiothoracic Institute, Brompton
Hospital, Fulham Road, London SW3 6HP, and *Deparment ofImmunology, Paterson
Laboratories, Christie Hospital and Holt Radium Institute, Manchester M20 9BX
Received 26 May 1982 Accepted 5 July 1982
Summary.-Human bronchoalveolar macrophages were separated from other free
lung cells by density sedimentation on Percoll gradients. They were then tested for
cytotoxicity against the human lung adenocarcinoma cell line A549, using a
Selenomethionine-75 post-labelling assay. The cytotoxicity of the macrophages
increased as the effector:target cell ratio was increased, approaching 100% at 20:1.
There was no significant difference in the cytotoxicity of macrophages isolated from
the lungs of bronchial-carcinoma or non-carcinoma patients. The highly cytotoxic
nature of the macrophages was not due to selection of a more potent cytotoxic
subpopulation of macrophages on the Percoll gradient, nor to a generally elevated
activation of the macrophages due to the pathological conditions in the patients'
lungs. An attempt to determine whether low concentrations of macrophages could
potentiate target-cell growth proved negative. Cytotoxicity of macrophages for
cultured lung target cells was not restricted to A549 cells and is not in accordance with
the view that defective bronchoalveolar macrophage cytotoxicity contributes to the
emergence ofbronchial neoplasia.
THAT FREE LUNG CELLS may be involved
in human pulmonary defence mechanisms,
both specific and non-specific, has been the
subject of great interest since fibreoptic
bronchoscopy made possible their recov-
ery for in vitro study (Territo & Golde,
1979; Harris et al., 1970; Warr & Russell
Martin, 1974; Yeager et al., 1974). A
potential role for mononuclear phagocytes
in defence against tumours has attracted
much attention and their cytotoxic cap-
ability is now well established. Broncho-
alveolar macrophages (BAM) from the
dog, guinea-pig and mouse have been
shown to be cytotoxic against cultured
tumour target cells (Gorman, 1979; Zwillig
& Campolito, 1977; Ryning et al., 1981). In
man, however, there are conflicting re-
ports; BAM have been shown to be
competent cytotoxic effector cells
(Lemarbe et al., 1980) or defective in this
activity (Bordignon et al., 1980).
In this study we have tested the
cytotoxicity of BAM from patients with
bronchial carcinoma and also from
patients with non-malignant pulmonary
conditions. Since human macrophages are
preferentially cytostatic for human target
cells (Hogg & Balkwill, 1981), we used a
cultured human lung adenocarcinoma cell
line (A549) as targets. This choice was also
determined by the fact that targets
derived from histologically distinctive
tissues may vary greatly in their suscepti-
bility to cell-mediated cytotoxic attack
(Lohmann-Matthes et at., 1978; Roder et
al., 1979).
MATERIALS AND METHODS
Patient details.-Patients undergoing diag-
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nostic fibreoptic bronchoscopy for suspected
cryptogenic fibrosing alveolitis, extrinsic
allergic alveolitis, sarcoidosis and bronchial
carcinoma, underwent bronchoalveolar lav-
age. Some of the patients were chronic
bronchitics. Each patient had received pre-
medication consisting of 0-6 mg atropine and
10 mg Omnopon. Treatment of symptoms
and/or accompanying ailments before bron-
choscopy ofthe whole patient group included
steroids (9/39); non-steroidal anti-inflam-
matory agents (2/39); bronchodilators (4/39);
agents affecting cardiovascular function
(11/39); antibiotics (5/39); cytotoxic agents
(2/39); antidepressants and sedatives (3/39);
analgesics (3/39); and no treatment (14/39).
The sample consisted of 31 males and 8
females whose combined age range was
19-75 years (mean 51 years). Smoking habits
were 7/39 non-smokers, 10/39 ex-smokers
(given up >2.5 months ago and previously
smoking 1-25 cigarettes/day, mean 15/day)
and 22/39 smokers (range 1-40 cigarettes/day,
mean 20/day).
Fibreoptic bronchoscopy and lavage.-Ethi-
cal considerations, contraindications and
technique have been discussed previously
(Cole et at., 1980). Briefly, after administra-
tion of 2-6 ml of a 4% lignocaine hydro-
chloride solution via the bronchoscope
(Olympus), its tip was impacted in a
segmental or more peripheral bronchus,
usually in the lower lobe ofthe lung opposite
to the disease, if unilateral. Lavage was
performed by injecting 60-200 ml of pre-
warmed (30°C), pH-corrected (pH7.0) physio-
logical saline through the bronchoscope and
aspirating the saline and bronchial secretions
immediately. These were collected in a sterile
siliconized glass trap maintained at 2-3°C on
ice. The lavage was repeated if necessary,
although no more than 200 ml total volume of
saline was used, and the retrieved opalescent
fluid was collected into the same trap.
Purification of bronchoalveolar macro-
phages.-Cells were collected from the lavage
fluid by centrifugation at 250 g for 10 min at
2-3°C. The resultant cell pellet was resus-
pended in HEPES-buffered 199 medium
(Flow Laboratories, Irvine, Scotland) without
antibiotics or serum. Thirty per cent (v/v)
Percoll (Pharmacia Fine Chemicals, Uppsala,
Sweden) gradients were prepared in the same
medium. Cells at 5-10 x 106 in a volume of
2-4 ml were layered on 10ml gradients
contained in plastic universal containers
(Sterilin, Middlesex, England) and centri-
fuged at 1500 g for 20 min at 2-3°C. The
gradient interface cells were then washed 3 x
in McCoy's 5A medium (Flow Laboratories,
Irvine, Scotland) with antibiotics (complete
McCoy's) without serum. In some experi-
ments the cells sedimenting to a pellet at the
bottom ofthe gradient were similarly washed.
Cells were finally suspended in complete
McCoy's plus 10% foetal calf serum (FCS)
(Flow Laboratories, Irvine, Scotland), at a
concentration of5 x 105/ml.
Determination ofBAMpurity.-Cytocentri-
fuge preparations were stained with May-
Grunwald-Giemsa and differential counts
made on the basis of morphology. In some
preparations the BAM cells were confirmed to
be non-specific esterase (NSE) positive.
Target cells.-The tissue culture cell line
(A549) (Giard et al., 1973) derived from a
human lung adenocarcinoma was used as
target cell in the cytotoxicity assay. It was
maintained in culture as an adherent mono-
layer in 45% Dulbecco's modified Eagle's
MEM/45% 199 medium, supplemented with
antibiotics plus 10% new born calf serum
(Flow Laboratories, Irvine, Scotland) and
when confluent, passaged after detachment
by trypsin.
Cytotoxicity assay.-This assay was based
upon the Selenomethionine-75 post-labelling
assay originally described by Brooks et al.,
(1978).
Appropriated volumes ofthe purified BAM
preparations were aliquoted into Linbro
microtest plates (Gibco Europe Ltd, Middle-
sex, England) to give a range of effector cell
concentrations from 2-5 x 103 to 105 cells/well.
In experiments where the effect of very low
numbers of effector cells was studied the
purified BAM ceils were diluted to 104/ml and
volumes aliquoted to give a range ofeffector-
cell concentrations from 50 to 1 25x 102
cells/well. Target cells were harvested during
exponential growth, washed and suspended in
complete McCoy's medium plus 10% FCS at a
concentration of 105/ml. These were then
added to the BAM in the microtest plates to
give a final target cell concentration of
5 x 103/well. The final volume ofeach well was
300 jul. Co-culture was for 64 h at 37°C in a
humidified atmosphere of5% CO2 in air. For
the last 16 h of co-culture, 10 ,ul of a
Selenomethionine-75 (Amersham Interna-
tional, England) solution was added to each
well, giving a final concentration of 0 5 ,uCi
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75Se/0-5 mm methionine/ml. The plates were
rinsed, dried and sealedin Benzoin compound.
Individual wells were cutout and the retained
75Se determined in a gamma counter.
Long-term assays of this type measure the
sum of cytolytic and cytostatic effects
mediated by effector-cell populations and for
ease of presentation these effects are col-
lectively described as "cytotoxicity".
The % cytotoxicity was calculated using
the following formula:
100-[(E+T)-E x 100] %
where: E+T denotes the mean 75Se counts
per 100 sec remaining in the quadruplicate
wells containing BAM and target cells, and: E
and T alone denote the mean counts
remaining in the quadruplicate wells con-
taining BAM or target cells alone, respec-
tively. (The 75Se-methionine labell-ng solution
contained a semi-saturating concentration of
unlabelled methionine, thus reducing to a
minimum the competition for 75Se-methion-
ine between the effector and target cell
populations in the co-culture: the use of X-
irradiated or actinomycin-D-treated target
cells in co-cultures has shown that there is no
enhancement of 75Se-methionine uptake and
retention by effector cells in the presence of
target cells (data not shown). The uptake and
retention of 75Se-methionine observed in
effector cells cultured alone is therefore an
accurate reflection of their 75Se-methionine
uptake and retention in co-culture and so is,
therefore, the 75Se-methionine calculated for
the target cells in the co-culture.
In some experiments cytotoxicity was
expressed as inhibition of target-cell growth,
the target cell numbers being represented
by their retention of 75Se (cts/100 sec/well
(x 103)).
Lymphocytes and polymorphonuclear leuco-
cytes (PMNL).-Defibrinated peripheral
blood was layered on Ficoll Triosil (FT)
gradients. Mononuclear leucocytes were re-
covered from the gradient interface and
lymphocytes purified by passage down a
Sephadex GIO column as described byJerrells
et al. (1979). This procedure has been shownto
enrich for a "natural killer" lymphocyte
population in rodent tumours (Moore &
Moore, 1979) and human peripheral blood
(Mantovani et al., 1979). PMNL were re-
covered from the FT gradient pellet after
removing the erythrocytes by sedimentation
through a Dextran gradient (Boyiim, 1968).
RESULTS
Free lung cells obtained by bronchoalveolar
lavage
The yield of viable free lung cells
obtained by bronchoalveolar lavage was
very variable (1-3-42.3 x 106 total) as was
the proportion of the major free lung cell
types: BAM, lymphocytes and PMNL
(Table). Since all these cells represented
potential cytotoxic effectors toward A549
target cells, the susceptibility ofthe latter
to the different populations was deter-
mined (Fig. 1). BAM decreased the growth
of A549 target cells in a dose-dependent
manner, being virtually 100% inhibitory
at the effector (E):target (T) cell ratios of
20: 1. The effect of PMNL was similar
although quantitatively less, at most being
approximately 50% inhibitory of target
TABLE.-The differential cell counts of bronchoalveolar cells before and after
Percoll separation
Before Percoll (%) After Percoll (o%)
A
Patient
J.B.
T.W.
G.T.
J.H.
I.J.
P.J.
J.w.
S.B.
BAM
86
84
83
62
80
70
67
94
Lymphs
5
6
8
32
13
2
1
1
PMN
9
10
9
6
7
28
33
5
BAM
96
82
93
84
93
93
94
97
Lymphs PMN
1
9
4
13
3
4
3
0
3
10
3
3
4
4
3
3
BAM =bronchoalveolar macrophages; lymphs =bronchoalveolar lymphocytes; PMN =bronchoalveolar
polymorphonuclear leucocytes.
Differential cell counts were performed on May-Grunwald-Giemsa-stained cytocentrifuge preparations.
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J J.H.) the BAM content was reduced. T.W.
BAM was a patient whose bronchoalveolar
lavage contained many small, sticky
mucus and/or surfactant particles and
J.H. suffered from extrinsic allergic alveo-
litis, the lavage containing many lympho-
blasts. Where the PMNL content of the
purified BAM population was greater than
5%, such as in the case of T.W., results
were not included in the cytotoxicity
calculations when obtained from assay
wells containing greater than 5 x 103
PMNL.
lymphocytes Comparison of cytotoxicity of BAM from
patients with and without bronchial
carcinoma
90
.
w90- PMN
r
70 leucocytes
70-
\
50-
30- r
0 25 50 100
Effector cells per well (x103)
0:1 5:1 10:1 20:1
Effector target cell ratio
FIG. 1. Susceptibility of A549 target cells to
the cytotoxicity of human bronchoalveolar
macrophages (BAM), peripheral blood
lymphocytes and peripheral blood polymor-
phonuclear (PMN) leucocytes. 57Se counts/
100 sec (x 103) indicates the 75Se retained
by the target cells and is directly propor-
tional to their numbers. Data points are the
mean + 1 s.d. of quadruplicate wells.
cell growth. By contrast, the lympocytes
had little cytotoxic effect even at an E:T
ratio of 20: 1. In order to remove cytotoxic
PMNL the concentrated free lung cell
suspensions were subjected to buoyant
density sedimentation separation on a
single-step Percoll gradient. The recovery
ofviable cells after Percoll purification was
very variable (5-68% of the original total
viable cell number) but the purity of the
recovered cells was usually high (Table).
In 2 cases shown in the Table (T.W. and
(Cytotoxicity assays were set up to test
the BAM from some of the patients at a
range ofE:T ratios from 0 5: 1 to 20: 1, or
as many of these ratios as the cell yield
allowed. The cytotoxicity of BAM from
the lungs of patients with confirmed
chronic bronchitis, cryptogenic fibrosing
alveolitis, sarcoidosis and primary bron-
chial carcinoma is shown in Fig. 2. Data
are also included on the cytotoxicity of
BAM from patients found on broncho-
scopy to be suffering only from mild
localized bronchial inflammation. The
cytotoxicity of each patient's BAM in-
creased as the E:T ratio was increased to
20:1. When the BAM cytotoxicity values
from the non-carcinoma patients were
combined at each E:T ratio and compared
with those of the bronchial carcinoma-
bearing patients, no significant difference
between the 2 groups was found at any
E:T ratio. Furthermore, in the non-
carcinoma group the range of cytotoxicity
values at each E:T ratio was composed of
an even distribution of data points
obtained using cells from all pathologies
and there was no consistent high or low
trend attributable to any particular dis-
ease. In both groups the BAM from
individual patients expressed consistently
high, medium or low levels of cytotoxicity
at each E:T ratio as compared with that of
the group as a whole. In one case, there
was positive target cell growth enhance-
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FIG. 2.-The cytotoxicity of bronchoalveolar
macrophages (BAM) from bronchial or
non-carcinoma-bearing patients for A549
target cells. The data points on the left-
hand side of each effector: target cell ratio
column are those obtained from individuals
diagnosed as having chronic bronchitis (0),
cryptogenic fibrosing alveolitis (*), allergic
alveolitis (*), sarcoidosis (A) or mild
bronchial inflammation (0O). On the right-
hand side are those from individuals
diagnosed with primary bronchial carci-
noma (V) or secondary melanoma deposits
in the bronchus (v). Each individual's
macrophages were tested for cytotoxicity
V8 A549 cells at each effector: target cell
ratio. The bars represent means.
ment (negative cytotoxicity) at 0 5: 1 and
1:1.
Is there a biased selection of BAM during
purification onPercoll gradients?
Preliminary experiments indicated that
the size and density of BAM were very
variable and that the more dense BAM
sedimented with the PMNL to a pellet at
the bottom of the gradient-being then
lost. Many BAM from smokers contain tar-
like inclusions in lysosomal bodies (unpub-
lished observations; Hunninghake et al.,
60
50
40
30 -
20 /
10
0 25 50 100
Effector ceLls per well ( x103)
0:1 5:1 10:1 20:1
Effector: target cell ratio
FIG. 3.-Cytotoxicity of bronchoalveolar
macrophages taken from the Percoll
gradient interface (-O-) of pellet (---),
mean + 1 s.d. of the mean.
1979; Hocking & Golde, 1979a) and, under
the conditions ofosmolality existing in the
Percoll gradients, these cells had a density
range comparable to the granular PMNL
and sedimented with them. Furthermore,
it has been reported by other workers
using freshly isolated rodent peritoneal
macrophages (Lee & Berry, 1977) or cells
adapted to tissue culture (Serio etal., 1979)
that there are subpopulations, separable
on the basis oftheir density, whose efficacy
as cytotoxic effector cells varies. The
observation that the carcinoma group
contained more smokers (10/15 compared
with 12/24 in the non-carcinoma group)
made it important to determine whether
the cytotoxicity observed in our experi-
ments was due to a more cytotoxic, less
dense subpopulationwhich was selected on
the Percoll gradient as these would
constitute a much smaller subpopulation
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of the BAM of the smoking, bronchial
carcinoma-bearing patients. We were for-
tunate to obtain several lavage fluids that
were almost PMNL free (< 3%) and were
able, therefore, to compare the cytotox-
icity of the BAM isolated from both the
Percoll gradient interface and pellet (Fig.
3). The cytotoxicity of both BAM popula-
tions increased as the E:T ratio was
increased although the mean cytotoxicity
ofthe pellet BAM was higher than that of
the interface BAM at the lower E:T ratios
and lower at the high E:T ratios.
However, at no ratio was this difference
statistically significant.
Can BAM enhance tumour cell growth?
The potentiation of the tumour target
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FIG. 4.-Cytotoxicity of bronchoalveolar
macrophages at low cell densities, for A549
target cells. The data points on the left-
hand side of each effector: target cell ratio
column are those obtained from individuals
diagnosed as having allergic alveolitis (-),
cryptogenic fibrosing alveolitis (*), mild
bronchial inflammation (DO) or sarcoidois
(A). On the right-hand side are those from
individuals diagnosed with primary bron-
chial carcinoma (V).
cell growth seen at 0 5: 1 and 1:1 with one
BAM preparation from a bronchial carcin-
oma-bearing patient (Fig. 2) raised the
question as to whether every BAM popula-
tion, under certain conditions, might be
able to enhance tumour cell growth. The
% cytotoxicity of this BAM preparation
was consistently very low at each E:T
ratio. As the dose-response curves of the
more cytotoxic BAM preparations were
approximately parallel to this one it was
possible that, under conditions where the
more cytotoxic BAM preparations were
further diluted, enhancement of tumour
cell growth might occur. However, only
one greatly diluted preparation of BAM
(from a sarcoidosis patient) potentiated
target cell growth (Fig. 4). The particuilar
BAM preparations from bronchial-carcin-
oma patients that were used in this
experiment appeared unable to do this,
suggesting that generally BAM cannot
enhance tumour-cell growth in vitro.
DISCUSSION
The aim of this study was to examine a
potential role for human BAM in the host
response to bronchial neoplasia. Although
the BAM constitutes the most numerous
cell type on the bronchial mucosal surface,
other potentially cytotoxic effector cells
are also present. Many of the patients
whose lungs were lavaged had pulmonary
abnormalities that were associated with an
increased number of lymphocytes and
PMNL infiltrating the bronchial lumen
from the blood (Hunninghake et al., 1979).
On examining whether these "contamina-
ting" cells might affect the results of the
BAM cytotoxicity assay it was found that
PMNL were cytotoxic for the A549 target
cells but lymphocytes were not. The
pathological changes accompanying many
of the pulmonary diseases and also smok-
ing habits cause variations in mucus
and/or surfactant secretion (Finley &
Ladman, 1972; Wanner, 1977). These
substances affected attempts to purify
BAM by adherence to plastic as removal of
non-adherent cells was usually accom-
panied by loss of most of the BAM which
x
0
0 U
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adhere avidly in aggregates to the mucus
or surfactant (Hocking & Golde, 1979b).
Purification of human peripheral blood
monocytes from lymphocytes and PMNL
has been achieved using buoyant density
sedimentation in Percoll gradients (Hardin
& Down, 1981; Pertoft et al., 1980; Ulmer
& Flad, 1979). Percoll was therefore used
in an attempt to purify BAM and we found
that it was possible to obtain highly
purified BAM. BAM are, however, very
heterogeneous in their size and density
distribution (Hunninghake et al., 1979;
Hocking & Golde, 1979a; Territo & Golde,
1979; Harris et al., 1970) and in each BAM
preparation the density of varying num-
bers of BAM coincided with that of the
PMNL and these cells were lost in the
pellet. Studies ofrodent peritoneal macro-
phages have suggested that cytotoxic
functions are the property of discrete
macrophage subpopulations separable by
their velocity of sedimentation in density
gradients. In this study the cytotoxicity of
the more dense (Percoll pellet) BAM had
some characteristics similar to those of
peripheral-blood monocytes (Swinburne
& Cole, 1982) in that they were more
cytotoxic than the less dense (Percoll
interface) BAM at low E:T ratios and less
cytotoxic at high E:T ratios, although
these differences were not statistically
significant. This would suggest that the
Percoll pellet BAM probably contained a
higher proportion of less differentiated
cells that had recently entered the bron-
chial lumen from the blood. These cells are
more dense mainly on account of their
greater nuclear: cytoplasmic volume ratio.
The fact that a more definitive separation
was not obtained was probably due to a
combination of 3 factors. The first was
that the buoyant density separation in this
case was partly on the basis of the size of
mucus/surfactant-cell aggregates, both
high- and low-density cells aggregating to
small mucus or surfactant fragments.
Second, individual BAM containing tar-
like inclusion (presumably more mature
cells) are relatively dense and generally
sedimentedin "thepellet" and, third, there
is some in vitro differentiation ofthese less
differentiated/more dense cells during the
64h assay period.
Patients undergoing fibreoptic broncho-
scopy were routinely anaesthetized locally
between the pharyngeal and upper bron-
chial regions with lignocaine. This has
been shown to affect macrophage anti-
body-dependent cytotoxicity (Kurisu et
al., 1978) but whether or not this affects
spontaneous cytotoxicity is unknown.
However, the fact that variable amounts
were administered to each patient, that
this was variable and probably greatly
diluted as the bronchus divided and its
mucosal surfaces were lavaged, and that
the BAM isolated from all the different
patients were cytotoxic in a similarly dose-
dependent manner with the majority
exceeding 70% cytotoxicity at 20: 1,
cumulatively suggests that the cyto-
toxicity detected here was not affected by
pre-exposure of the different preparations
ofBAM to lignocaine.
Similarly, the fact that the patients
studied were very heterogeneous in terms
of age, smoking habits, past and present
clinical history and drug treatment
appears not to have affected the ability of
their BAM to be cytotoxic in this assay.
However, perturbation ofthe cytotoxicity
of individual BAM preparations, e.g. due
to patient pretreatment with steroids,
cainot be discounted. Of particular inter-
est was the fact that there was no
significant difference between the BAM
from patients diagnosed as having bron-
chial carcinoma (the majority of smokers)
and other pulmonary disorders (the
majority ofnon-smokers).
BAM were also cytotoxic for two
additional human lung cell lines, E14
originating from a human lung squamous-
cell carcinoma (Fischer & Wetterlein,
1977) and HS853 (American Type Culture
Collection), a culture of fibroblast mor-
phology originating from non-carcinoma-
tous human lung tissue (data not shown).
However, whether fresh lung tumour cells,
unadapted to tissue culture, are sensitive
to BAM was not investigated. However, in
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this context Vose (1978) has shown that
macrophages isolated from within human
lung tumours can express cytolytic activ-
ity against fresh tumour targets. Further-
more Rhodes et al. (1981) have shown that
BAM isolated from the vicinity of a
malignant bronchial lesion have a reduced
Fc-receptor expression and this is possibly
due to tumour-derived factors exuded into
the bronchial lumen. Whether this may
affect the BAM migration towards, infil-
tration of, and subsequent cytotoxic
activity within a bronchial tumour needs
further examination. The cytotoxicity of
BAM for A549 target cells is known to be
due, at least in part, to cytolytic activity
(Swinburne & Cole, 1982). Our data are
consistent with those of Lemarbre et al.
(1980) but are not comparable with those
of Bordignon et al. (1980), who suggested
that there is anintrinsic tumoricidal defect
in BAM. These discrepancies may be due
either to differences in the BAM purifica-
tion procedures used, i.e. selection by
adherence or density sedimentation, or to
the different target cells used to assess
BAM cytotoxicity. Bordignon et al. (1980)
used SV40 transformed murine kidney-
tumour cells as target cells.
Within the non-carcinoma group there
were individuals who were bronchoscoped
to investigate "non-resolving cough" and
haemoptysisbutwho onbronchoscopywere
found to have no more abnormality than a
localized mild inflammation of the bron-
chial mucosa with no obvious cause. Lung
lavage in these patients, as with most
others, was carried out in an unaffected
lobe, and the cytotoxicity of these BAM
preparations was similar, both quali-
tatively and quantitatively, to that of
BAMfrom the various provenpathological
states. This would argue against the
potent cytotoxicity of BAM detected in
this assay being due to a generalized
activation relating to smoking habits or a
pathological disorder occurring in the
bronchi (Hunninghake et al., 1979) but is
more probably attributable to an endo-
genously high state ofactivation normally
present in the BAM.
Ithas been shown in several studies that
under certain conditions macrophages
may actually enhance growth ofsome cell
types (Wing & Remington, 1980; Keller,
1975; Leibovich & Ross, 1976; DeLustro et
al., 1980: Greenburg & Hunt, 1978)
including tumour cells (Binderup et al.,
1979; Zipori & Bol, 1979; Nathan & Terry,
1975; Evans, 1979; Mantovani, 1978). It
was therefore of interest when one BAM
preparation showed significant target-cell
growth enhancement. The inability to find
further evidence of this in other BAM
preparations simply by manipulating the
E:T ratio was either indicative ofthe fact
that generally these macrophages were
incapable of promoting growth enhance-
ment or that other, as yet undefined,
culture conditions are required before this
is manifested in vitro.
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